PharmaMar inks deal worth up to $1 billion for lurbinectedin in the USA

20 December 2019
pharmamarbig

Just a couple of days after filing for approval of the drug as a treatment small cell lung cancer (SCLC) with the US Food and Drug Administration, Spain’s PharmaMar (MC: PHM) has signed an important licensing deal for Zepsyre (lurbinectedin).

PharmaMar has entered into an exclusive licensing agreement with Ireland-incorporated Jazz Pharmaceuticals (Nasdaq: JAZZ) for lurbinectedin in the USA, with the news pushing the Spanish firm’s share higher on Thursday and a further 3% to 2.99 euros this morning. Jazz’s stock gained nearly 2.6% to $152,27 by close of trading on Thursday.

Under the terms of this agreement, PharmaMar will receive an upfront of $200 million with potential regulatory milestone payments of up to $250 million on the achievement of accelerated and/or full regulatory approval of lurbinectedin by FDA within certain timelines.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical